Related references
Note: Only part of the references are listed.Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Senthamil R. Selvan et al.
CURRENT CANCER DRUG TARGETS (2016)
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2015)
Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy
Christopher J. D. Austin et al.
DRUG DISCOVERY TODAY (2015)
Research progress of indoleamine 2,3-dioxygenase inhibitors
Tianze Jiang et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Myelosuppression After Frontline Fludarabine, Cyclophosphamide, and Rituximab in Patients With Chronic Lymphocytic Leukemia Analysis of Persistent and New-Onset Cytopenia
Paolo Strati et al.
CANCER (2013)
Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)
Eduard Dolusic et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice
Shuangshuang Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
Marine Natural Products and Other Derivatives as Potent Indoleamine 2,3-Dioxygenase Inhibitors
Evelyne Delfourne
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2012)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase
Sara A. Rafice et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan
Jun Zeng et al.
CANCER RESEARCH (2009)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Marrying immunotherapy with chemotherapy: why say IDO?
AJ Muller et al.
CANCER RESEARCH (2005)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Opinion - Immunotherapy and chemotherapy - a practical partnership
RA Lake et al.
NATURE REVIEWS CANCER (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division
GK Lee et al.
IMMUNOLOGY (2002)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Share Paper
